SAM
TXMD icon

Sectoral Asset Management’s TherapeuticsMD TXMD Stock Holding History

Sectoral Asset Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-724
Closed -$45K – 172
2020
Q2 		$45K Buy
+724
New +$42.2K ﹤0.01% 191

Other funds holding TXMD

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

Sectoral Asset Management's TXMD Position: Q3 2020 in Review

Sectoral Asset Management sold out of TherapeuticsMD (TXMD) in Q3 2020, closing a stake of 724 shares — an estimated $45K sold.

Sectoral Asset Management first reported a position in TXMD in Q2 2020 and held it in 1 quarter. The position peaked at $45K in Q2 2020. 142 funds tracked by Wall St. Rank hold TXMD as of Q3 2020.

  • Sectoral Asset Management reported no remaining TherapeuticsMD position as of Q3 2020 after selling out during the quarter.
  • Sectoral Asset Management sold 724 TherapeuticsMD shares in Q3 2020, an estimated $45K.
  • Sectoral Asset Management first reported a position in TherapeuticsMD in Q2 2020 and held it in 1 quarter.
  • Sectoral Asset Management's TherapeuticsMD position peaked at $45K in Q2 2020.
  • 142 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2020.

Based on Sectoral Asset Management's 13F filing for Q3 2020, filed 13 Nov 2020.